Vortioxetine

Generic Name: Vortioxetine

Brand Names: Brintellix, Trintellix

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₂N_₂S

CAS Number: 508233-74-7

Unique Ingredient Identifier: 3O2K1S3WQV

Background: Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of se...

Indication: 用于治疗重度抑郁症成人患者。

Associated Conditions: Major Depressive Disorder (MDD)

Associated Therapies: -

Clinical Trials

Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Desvenlafaxine
Drug: Vortioxetine

First Posted Date: 2020-06-25

Last Posted Date: 2022-02-14

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 605

Registration Number: NCT04448431

Locations: 🇦🇷
INAPsi (Instituto Nacional de Psicopatologia), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇲🇽
CRI Centro Regiomontano de Investigacion SC, Monterrey, Nuevo Leon, Mexico
🇷🇺
Leningrad Regional Psychoneurological Dispensary, Roshchino, Leningrad Region, Russian Federation

and more 77 locations

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

Completed

Conditions: Major Depression

Interventions: Drug: Desvenlafaxine
Drug: Escitalopram
Drug: Paroxetine
Drug: Fluoxetine
Drug: Mirtazapine
Drug: Duloxetine
Drug: Sertraline
Drug: Venlafaxine
Drug: Tianeptine
Drug: Vortioxetine
Drug: Bupropion

First Posted Date: 2020-06-24

Last Posted Date: 2024-12-09

Lead Sponsor: Pfizer

Target Recruit Count: 370212

Registration Number: NCT04446039

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

Tolerability, Safety and Efficacy of Vortioxetine

Phase 4

Recruiting

Conditions: Depression

Interventions: Drug: Vortioxetine

First Posted Date: 2020-03-10

Last Posted Date: 2023-06-22

Lead Sponsor: IRCCS San Raffaele Roma

Target Recruit Count: 20

Registration Number: NCT04301492

Locations: 🇮🇹
IRCCS San Raffaele, Roma, Italy
🇮🇹
IRCCS San Raffaele Roma, Rome, Italy

Vortioxetine in Patients With Depression and Early Dementia

Phase 4

Completed

Conditions: Major Depressive Disorder
Dementia

Interventions: Drug: Vortioxetine

First Posted Date: 2020-03-04

Last Posted Date: 2022-08-08

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 82

Registration Number: NCT04294654

Locations: 🇫🇷
Centre de Recherche-Hopital Geriatrique de Charpennes, Villeurbanne, France
🇪🇪
Marienthali Kliinik, Tallinn, Estonia
🇮🇹
Azienda Ospedaliera di Perugia - Policlinico Monteluce, Perugia, Umbria, Italy

and more 21 locations

Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine

First Posted Date: 2020-02-28

Last Posted Date: 2022-03-18

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 400

Registration Number: NCT04288895

Locations: 🇮🇳
Vinaya Hospital & Research Centre (IN1007), Mangalore, Karnataka, India
🇮🇳
BJ Medical College and Civil Hospital (IN028), Ahmedabad, Gujarat, India
🇮🇳
Mangala Hospital & Mangala Kidney Foundation (IN1006), Mangalore, Karnataka, India

and more 21 locations

Vortioxetine for Cancer Patients With Depression: An Observational Study

Conditions: Major Depressive Disorder
Cancer

Interventions: Drug: Vortioxetine

First Posted Date: 2020-02-05

Last Posted Date: 2020-02-05

Lead Sponsor: University of Malaya

Target Recruit Count: 140

Registration Number: NCT04253678

Locations: 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾
Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
🇲🇾
Hospital Raja Permaisuri Bainun, Ipoh, Ipoh, Perak, Malaysia

and more 5 locations

Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)

Phase 4

Completed

Conditions: Anxiety Disorders
MDD

Interventions: Drug: Vortioxetine

First Posted Date: 2020-01-07

Last Posted Date: 2021-04-20

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 100

Registration Number: NCT04220996

Locations: 🇵🇱
Niepubliczny Zaklad Opieki Psychiatrycznej Mentis (PL0004), Leszno, Poland
🇵🇱
Centrum Medyczne Luxmed Sp.Z O.O. (PL0006), Lublin, Poland
🇵🇱
Clinical Research Center Spolka z ograniczona odpowiedzialnoscia Medic-R Sp.k. (PL0007), Poznan, Poland

and more 18 locations

Vortioxetine vs Sertraline in Mexicans

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus
Depression

Interventions: Drug: Sertraline
Drug: Vortioxetine

First Posted Date: 2019-06-07

Last Posted Date: 2019-06-13

Lead Sponsor: Universidad Juárez Autónoma de Tabasco

Target Recruit Count: 21

Registration Number: NCT03978286

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

Phase 3

Withdrawn

Conditions: Depressive Disorder, Major

Interventions: Drug: Placebo
Drug: Rapastinel
Drug: Vortioxetine

First Posted Date: 2019-02-27

Last Posted Date: 2019-07-19

Lead Sponsor: Naurex, Inc, an affiliate of Allergan plc

Registration Number: NCT03855865

Study With Vortioxetine on Emotional Functioning in Patients With Depression

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine

First Posted Date: 2019-02-08

Last Posted Date: 2020-03-24

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 150

Registration Number: NCT03835715

Locations: 🇫🇷
Cabinet Psyche (FR0012), Douai, France
🇱🇹
JSC Romuvos Klinika (LT0002), Kaunas, Lithuania
🇪🇸
University of Oviedo (ES0011), Oviedo, Spain

and more 20 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy